JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

Search

Certara Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

7.22 -2.04

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

7.19

Max

7.37

Pagrindiniai rodikliai

By Trading Economics

Pajamos

3.5M

1.5M

Pardavimai

46K

105M

P/E

Sektoriaus vid.

118.571

84.243

Pelno marža

1.458

Darbuotojai

1,487

EBITDA

-6.5M

23M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+60.03% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-02-26

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-557M

1.3B

Ankstesnė atidarymo kaina

9.26

Ankstesnė uždarymo kaina

7.22

Naujienos nuotaikos

By Acuity

50%

50%

139 / 352 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Certara Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-08 23:57; UTC

Rinkos pokalbiai

Uranium Outlook Heats Up on Rising Demand, Uncertain Supply -- Market Talk

2026-02-08 23:47; UTC

Rinkos pokalbiai

Gold Rises Amid Growing U.S.-Iran Tensions -- Market Talk

2026-02-08 23:43; UTC

Rinkos pokalbiai

Nikkei Likely to Rise Sharply After Takaichi's Election Win -- Market Talk

2026-02-08 23:34; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-02-08 23:34; UTC

Rinkos pokalbiai

Landslide Election Victory of Japan's LDP Positive for Risk Assets -- Market Talk

2026-02-08 23:26; UTC

Rinkos pokalbiai

Yen Skittish; Nikkei Jumps On LDP Landslide -- Market Talk

2026-02-08 22:55; UTC

Uždarbis

DBS Group 4Q Net S$2.36B Vs. Net S$2.62B >D05.SG

2026-02-08 22:55; UTC

Uždarbis

DBS Group 4Q Net Interest Income S$3.59B Vs. S$3.83B>D05.SG

2026-02-08 22:55; UTC

Uždarbis

DBS Board Proposes 4Q Dividend of 66 Singapore Cents/share>D05.SG

2026-02-08 22:55; UTC

Uždarbis

DBS Group: 2025 Total Dividend at S$3.06/share >D05.SG

2026-02-08 22:55; UTC

Uždarbis

DBS Group 4Q Net Weighed by Higher Tax Expense, Absence of Non-Recurring Gains Recrorded Last Year >D05.SG

2026-02-08 22:55; UTC

Uždarbis

DBS Group 4Q Total Income S$5.33B Vs. S$5.51B>D05.SG

2026-02-08 21:43; UTC

Rinkos pokalbiai

FX Intervention Watch Resumes After Japan Election Result -- Market Talk

2026-02-08 21:16; UTC

Rinkos pokalbiai

Right Of Australian Politics Reshaped as One Nation Surges -- Market Talk

2026-02-08 21:15; UTC

Rinkos pokalbiai

Japan's Election Outcome to Revive Takaichi Trade -- Market Talk

2026-02-07 09:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-02-07 09:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-02-07 05:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-02-07 02:46; UTC

Įsigijimai, susijungimai, perėmimai

Big Money, High Anxiety -- Barrons.com

2026-02-06 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-02-06 21:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-02-06 21:40; UTC

Įsigijimai, susijungimai, perėmimai

Verizon Insiders Rarely Sell Company Stock. This Insider Just Did. -- Barrons.com

2026-02-06 21:22; UTC

Rinkos pokalbiai

Mexico's Inflation Seen Accelerating in January -- Market Talk

2026-02-06 21:17; UTC

Uždarbis

Toyota Smashes Earnings Estimates. It's Getting a New CEO. -- Barrons.com

2026-02-06 21:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-02-06 21:14; UTC

Įsigijimai, susijungimai, perėmimai

Justice Department Casts Wide Net on Netflix's Business Practices in Merger Probe -- Update

2026-02-06 21:13; UTC

Uždarbis

How the Software Panic Hit BDC Stocks -- and Why Some Might Be Worth Buying -- Barrons.com

2026-02-06 21:13; UTC

Uždarbis

Amazon, Strategy, Robinhood, Novo Nordisk, Molina, Stellantis, Hub Group, and More Stock Market Movers -- Barrons.com

2026-02-06 21:04; UTC

Rinkos pokalbiai

Gold Closes Out Volatile Week on Higher Note -- Market Talk

2026-02-06 20:34; UTC

Uždarbis

Tech Had an Awful Earnings Season. Other Stocks Are Saving the Day. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Certara Inc Prognozė

Kainos tikslas

By TipRanks

60.03% į viršų

12 mėnesių prognozė

Vidutinis 11.57 USD  60.03%

Aukščiausias 13 USD

Žemiausias 9 USD

Remiantis 9 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Certara Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

9 ratings

6

Pirkti

3

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

11.27 / 12.79Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Very Strong Bullish Evidence

Ilgalaikis periodas

Strong Bullish Evidence

Rinkos nuotaikos

By Acuity

139 / 352 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Vidutinis

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Certara Inc

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
help-icon Live chat